Walder Wyss has acted as legal counsel to Swisscanto Invest by Zürcher Kantonalbank in connection with the series B financing round of Sulzer & Schmid Laboratories, an independent Swiss technology company of next-generation technology
Tags :Walder Wyss
Private investment company Drs Investment sells 100 per cent of the shares in the Swiss software company Xelog to Prologistik Holding. The acquisition of Xelog, the Swiss logistics software specialist, is part of Prologistik’s strategy
Walder Wyss acted as legal counsel to Alentis Therapeutics on the USD 67 million series B financing round. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors Biomed Partners, BB Pureos
Walder Wyss won an appeal to the Federal Court in connection with a lease expulsion matter. The legal team In particular the law firm acted with partner Nicolas Iynedjian (real estate, pictured) and associate
Komgo – the trade finance blockchain joint venture – has successfully closed its third funding round by raising CHF 26 million. The round received a high level of interest from both new and returning investors. The investment brought
Senevita took over the Sensato Group consisting of seven locations with around 200 employees. This acquisition took place in mid of May 2021 and ended on June 1st 2021. The legal team Walder Wyss acted as legal counsel
The insurtech startup Wefox – with its Zurich based parent company Wefox Holding (formerly FinanceApp) – has completed on 1 June a Series C financing round of 650 million USD. The legal team Walder Wyss advised the company in
Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside
Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to
MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany.
